Recent Developments in Immuno-oncology: Biomarkers, Pan-tumor Studies, Novel Treatment Combinations, and the Management of Adverse Events

Track 2: Biomarkers for Immunotherapies Across Tumor Type

View Activity

Please note this program was recorded before the March 2020 expanded indication for durvalumab. Durvalumab is now approved in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

PROGRAM CHAIRS

Arjun V. Balar, MD
Assistant Professor of Medicine
Director, Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, NY

Jeffrey S. Weber, MD, PhD
Deputy Director, Laura and Isaac Perlmutter Cancer Center
Co-Director, Melanoma Research Program
NYU Langone Health
Professor of Medicine, NYU School of Medicine
New York, NY

FACULTY PRESENTER

Isabella C. Glitza, MD, PhD
Assistant Professor
University of Texas MD Anderson Cancer Center
Houston, TX

PROGRAM OVERVIEW

This case-based enduring activity will cover the diagnosis, treatment. and management of patients with cancer who are treated or eligible for treatment with immunotherapy.

TARGET AUDIENCE

This initiative is designed to meet the educational needs of oncologists, oncology pharmacists, oncology nurses, and other healthcare professionals and teams involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Review the clinical utility of currently identified immune-related biomarkers and the benefits and limitations of different immune biomarker testing methodologies
  • Incorporate immune-related biomarker testing to identify patients most likely to benefit from cancer immunotherapies administered alone or in combination
  • Describe immune-related biomarker-driven pan-tumor studies, their designs, and the implications of their results for patient management

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with cancer who are treated or eligible for treatment with immunotherapy.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

ONCC STATEMENT

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

PHARMACISTS

In support of improving patient care, this activity has been planned and implemented by Amedco, LLC and Med Learning Group. Amedco, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco, LLC designates this enduring activity for a maximum of 1.0 knowledge-based contact hour for pharmacists/technicians. Learners should claim only the credit commensurate with the extent of their participation in the activity.
NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Balar has received consultant fees from Merck, Genentech, AstraZeneca, Pfizer, and Seattle Genetics; and received fees for non-CME/CE services received directly from a commercial interest or its agent from Merck, Genentech, and AstraZeneca.

Dr. Weber has intellectual property or is a patent holder on a PD-1 biomarker by Biodesix and on a CTLA-4 biomarker by Moffitt Cancer Center. He has received consulting fees from BMS, Merck, Novartis, Pfizer, and AstraZeneca. He has been contracted for research with NextCure; and has ownership interests in Biond, Altor, and CytoMx.

Dr. Glitza has received consultant fees from Bristol-Myers Squibb, Novartis, and ARRAY; and has been contracted for research with Merck and Bristol-Myers Squibb. She also serves on the speakers’ bureau for ARRAY and Novartis.

The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Brianna Hanson, Outcomes and Accreditation Coordinator for Med Learning Group has nothing to disclose.
Nicole Longo, DO, FACOI, Director, Medical and Scientific Services for Med Learning Group has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: February 28, 2020

EXPIRATION DATE: February 28, 2021

ENDURING MATERIAL LEARNER NOTIFICATION

IC-ONC: Enduring Biomarker track – Recent Developments in Immuno-oncology: Biomarkers for Immunotherapies Across Tumor Type
Date of CE Release: February 28, 2020
Date of CE Expiration: February 28, 2021
Location: Online

Acknowledgement of Financial Commercial Support

Bristol-Myers Squibb, Merck

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available.

If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Pharmacists

In support of improving patient care, this activity has been planned and implemented by Amedco, LLC and Med Learning Group. Amedco, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco,

LLC designates this enduring activity for a maximum of 1.0 knowledge-based contact hours for pharmacists/technicians. Learners should claim only the credit commensurate with the extent of their participation in the activity.
UAN(s): JA4008163-9999-20-017-H04-P, JA4008163-9999-20-017-H04-T
NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

Objectives – After attending this program you should be able to:
1. Review the clinical utility of currently identified immune-related biomarkers and the benefits and limitations of different
immune biomarker testing methodologies.
2. Incorporate immune-related biomarker testing to identify patients most likely to benefit from cancer immunotherapies
administered alone or in combination.
3. Describe immune-related biomarker-driven pan-tumor studies, their designs, and the implications of their results for patient
management.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco, LLC. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

Name Relationship : Commercial Interest
Dr. Balar Consultant: Merck, Genentech, AstraZeneca, Pfizer, and Seattle Genetics; Fees from Non-CME Services: Merck, Genentech, and AstraZeneca
Dr. Weber Consultant: BMS, Merck, Novartis, Pfizer, and AstraZeneca; Contracted Research: NextCure; Ownership Interest: Biond, Altor, and CytoMx
Dr. Glitza Consultant: Bristol-Myers Squibb, Novartis, ARRAY; Contracted Research: Merck, Bristol-Myers Squibb; Speakers’ Bureau: ARRAY, Novartis
Matthew Frese NA
Christina Gallo NA
Brianna Hanson NA
Nicole Longo NA
Scott McGee-Plys NA
Jessica McMullen NA

View Activity

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.